Araj Brittany N, Swihart Bruce, Morrison Robert, Gonzales Hurtado Patricia, Teo Andrew, Mahamar Almahamoudou, Attaher Oumar, Diarra Bacary S, Gaoussou Santara, Issiaka Djibrilla, Dicko Alassane, Duffy Patrick E, Fried Michal
Molecular and Pathogenesis Biomarkers Section, Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland, USA.
mSystems. 2021 Jun 29;6(3):e0034721. doi: 10.1128/mSystems.00347-21. Epub 2021 Jun 15.
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a variant surface antigen family expressed on infected red blood cells that plays a role in immune evasion and mediates adhesion to vascular endothelium. PfEMP1s are potential targets of protective antibodies as suggested by previous seroepidemiology studies. Here, we used previously reported proteomic analyses of PfEMP1s of clinical parasite isolates collected from Malian children to identify targets of immunity. We designed a peptide library representing 11 PfEMP1 domains commonly identified on clinical isolates by membrane proteomics and then examined peptide-specific antibody responses in Malian children. The number of previous malaria infections was associated with development of PfEMP1 antibodies to peptides from domains CIDRα1.4, DBLγ11, DBLβ3, and DBLδ1. A zero-inflated negative binomial model with random effects (ZINBRE) was used to identify peptide reactivities that were associated with malaria risk. This peptide selection and serosurvey strategy revealed that high antibody levels to peptides from DBLγ11 and DBLδ1 domains correlated with decreased parasite burden in future infections, supporting the notion that specific PfEMP1 domains play a role in protective immunity. infection causes devastating disease and high mortality in young children. Immunity develops progressively as children acquire protection against severe disease, although reinfections and recrudescences still occur throughout life in areas of endemicity, partly due to parasite immunoevasion via switching of variant proteins such as Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) expressed on the infected erythrocyte surface. Understanding the mechanisms behind antibody protection can advance development of new therapeutic interventions that address this challenge. PfEMP1 domain-specific antibodies have been linked to reduction in severe malaria; however, the large diversity of PfEMP1 domains in circulating parasites has not been fully investigated. We designed representative peptides based on B cell epitopes of PfEMP1 domains identified in membranes of clinical parasite isolates and surveyed peptide-specific antibody responses among young Malian children in a longitudinal birth cohort. We examined previous infections and age as factors contributing to antibody acquisition and identified antibody specificities that predict malaria risk.
恶性疟原虫红细胞膜蛋白1(PfEMP1)是感染的红细胞上表达的一种可变表面抗原家族,在免疫逃避中起作用,并介导与血管内皮的黏附。如先前的血清流行病学研究所示,PfEMP1是保护性抗体的潜在靶点。在此,我们利用先前报道的对从马里儿童分离的临床寄生虫株的PfEMP1进行的蛋白质组学分析来确定免疫靶点。我们设计了一个肽库,该肽库代表通过膜蛋白质组学在临床分离株上常见鉴定出的11个PfEMP1结构域,然后检测了马里儿童中肽特异性抗体反应。既往疟疾感染的次数与针对来自结构域CIDRα1.4、DBLγ11、DBLβ3和DBLδ1的肽的PfEMP1抗体的产生有关。使用具有随机效应的零膨胀负二项式模型(ZINBRE)来确定与疟疾风险相关的肽反应性。这种肽选择和血清学调查策略表明,针对来自DBLγ11和DBLδ1结构域的肽的高抗体水平与未来感染中寄生虫负荷的降低相关,支持了特定PfEMP1结构域在保护性免疫中起作用的观点。感染在幼儿中会导致毁灭性疾病和高死亡率。随着儿童获得针对严重疾病的保护,免疫力会逐渐发展,尽管在流行地区,一生中仍会发生再感染和复发,部分原因是寄生虫通过切换感染红细胞表面表达的可变蛋白(如恶性疟原虫红细胞膜蛋白1(PfEMP1))进行免疫逃避。了解抗体保护背后的机制可以推动应对这一挑战的新治疗干预措施的开发。PfEMP1结构域特异性抗体已与严重疟疾的减少相关;然而,循环寄生虫中PfEMP1结构域的巨大多样性尚未得到充分研究。我们基于在临床寄生虫分离株膜中鉴定出的PfEMP1结构域的B细胞表位设计了代表性肽,并在一个纵向出生队列中调查了马里幼儿中肽特异性抗体反应。我们将既往感染和年龄作为促成抗体获得的因素进行了研究,并确定了预测疟疾风险的抗体特异性。